SEMA7A: A Potential Drug Target and Biomarker (G8482)

Target Name: SEMA7A

NCBI ID: G8482

SEMA7A

SEMA7A: A Potential Drug Target and Biomarker

Semaphorin 7A (SEMA7A), also known as GPI membrane anchor, is a protein that is expressed in various cell types of the human body. It is a type of transmembrane protein that is involved in cell-cell adhesion and in the regulation of intracellular signaling pathways. SEMA7A has also been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, SEMA7A has potential as a drug target and biomarker.

SEMA7A is a member of the GPI (Glycophorin A) family, which includes proteins that are involved in cell-cell adhesion and signaling. GPI proteins are characterized by their ability to interact with ganglioside receptors, which are found on the surface of various cell types. This interaction allows GPI proteins to play important roles in the regulation of intracellular signaling pathways and the development of various diseases.

One of the unique features of SEMA7A is its ability to interact with the protein FERMT1 (F-actinin-related protein 1). FERMT1 is a protein that is involved in the regulation of cell-cell adhesion and that is expressed in various cell types, including neurons and muscle cells. SEMA7A has been shown to interact with FERMT1 and to play a role in the regulation of cell-cell adhesion.

In addition to its role in cell-cell adhesion, SEMA7A is also involved in the regulation of intracellular signaling pathways. It has been shown to be involved in the regulation of various signaling pathways, including the TGF-β pathway and the PI3K/Akt signaling pathway. TGF-β is a signaling pathway that is involved in the regulation of cell growth, differentiation, and survival, while PI3K/Akt is a signaling pathway that is involved in the regulation of cell survival and metabolism.

SEMA7A has also been shown to be involved in the development and progression of various diseases. For example, SEMA7A has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. It has also been shown to be involved in the development of autoimmune disorders, such as rheumatoid arthritis and type 1 diabetes.

As a result of its involvement in various signaling pathways and its ability to interact with important proteins, SEMA7A has potential as a drug target and biomarker. Researchers are currently working to develop drugs that can specifically target SEMA7A and to use it as a biomarker for the diagnosis and treatment of various diseases.

In conclusion, SEMA7A is a protein that is involved in cell-cell adhesion and in the regulation of intracellular signaling pathways. Its unique ability to interact with important proteins and its involvement in various diseases make it a potential drug target and biomarker. Further research is needed to fully understand the role of SEMA7A in the regulation of intracellular signaling pathways and its potential as a drug target and biomarker.

Protein Name: Semaphorin 7A (John Milton Hagen Blood Group)

Functions: Plays an important role in integrin-mediated signaling and functions both in regulating cell migration and immune responses. Promotes formation of focal adhesion complexes, activation of the protein kinase PTK2/FAK1 and subsequent phosphorylation of MAPK1 and MAPK3. Promotes production of pro-inflammatory cytokines by monocytes and macrophages. Plays an important role in modulating inflammation and T-cell-mediated immune responses. Promotes axon growth in the embryonic olfactory bulb. Promotes attachment, spreading and dendrite outgrowth in melanocytes

The "SEMA7A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SEMA7A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets